



AMENDMENT

In the Claims:

The following listing reflects amendments to the claims and replaces all prior versions and listings of claims in this application.

1-16 (canceled)

17. (New) An immunogenic composition comprising a first antigen and a second antigen, wherein: (a) the first antigen is an oligosaccharide from serogroup C of *N. meningitidis* (NmC) conjugated to a carrier; and (b) the second antigen is proteoliposomic vesicles from serogroup B of *N. meningitidis* (NmB). *protein*

18. (New) The composition of claim 17, wherein said first antigen is conjugated to a protein carrier.

19. (New) The composition of claim 18, wherein said protein is CRM₁₉₇. *carrier*

20. (New) The composition of claim 17, wherein said NmC oligosaccharide contains about 12 to about 22 repeating units from serogroup C capsular polysaccharide. *N. meningitidis*

21. (New) The composition of claim 17, wherein said NmB is strain 44/76 (B15:P1.7, 16:L3,7,9). *H*

22. (New) The composition of claim 17, wherein said proteoliposomic vesicles are produced a deoxycholate extraction process.

23. (New) The composition of claim 17, wherein said composition further

comprises aluminum hydroxide or MF59.

24. (New) The composition of claim 17, wherein said composition comprises a carrier comprising polylactic acids and/or polyglycolic acids.

25. (New) The composition of claim 17, wherein said composition comprises immunologically effective amounts of the first and the second antigen.

26. (New) An immunogenic composition comprising an immunologically effective amount of a first antigen and an immunologically effective amount of a second antigen, wherein: (a) the first antigen is an oligosaccharide from serogroup C on *N. meningitidis* (NmC), conjugated to CRM₁₉₇, and contains from 12 to 22 repeating units from the NmC capsular polysaccharide and (b) the second antigen is proteoliposomic vesicles from strain 44/76 (B15:P1.7, 16:L3,7,9) of serogroup B of *N. meningitidis* (NmB), wherein said proteoliposomic vesicles are produced by a deoxycholate extraction process.

27. (New) The composition of claim 26, wherein said composition further comprises aluminum hydroxide or MF59.

28. (New) The composition of claim 26, wherein said composition comprises a carrier comprising polylactic acids and/or polyglycolic acids.

29. (New) A method of inducing an immunologic response to NmB and NmC in a mammalian subject, comprising administering an immunologically effective amount of an immunogenic composition of any of claims 17-28 to said mammalian subject.